The association of FAT1 mutations with therapeutic outcomes in AML, especially in receiving venetoclax combination.

Front Oncol · 2025 · PMC12000698 · PMID 40242237

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Additionally, FAT1 mutant patients showed a trend toward improved progression-free survival (PFS) compared to wild-type patients, although the difference in PFS was not statistically significant.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.